Skip to main content
Premium Trial:

Request an Annual Quote

OriGene Technologies Raises $16M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OriGene Technologies has raised $16 million in a Series B financing led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO, the firm said yesterday.

The Rockville, Md.-based genetic tools company said that previous investors Morningside Venture Investments and President International Development also participated in the round.

OriGene intends to use the funds to help build its TrueMAB monoclonal antibody collection with an aim of covering the majority of the human proteome. Among the firms other products are cDNA and shRNA clone collections; over 5,000 purified human proteins; 100,000 highly validated human tissues; and assay products based on Luminex's multiplex platform.

"The funding will propel us closer to meeting our goal of building the largest monoclonal antibody collection in the world covering the entire human genome of approximately 20,000 genes," Wei-Wu He, OriGene's chairman and CEO, said in a statement.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.